Immunotherapy in Myeloproliferative Diseases

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Jul 2

PMID 32604862

Citations 13

Authors

Lukas M Braun

Robert Zeiser

Affiliations

Soon will be listed here.

Abstract

Myeloproliferative diseases, including myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), are driven by genetic abnormalities and increased inflammatory signaling and are at high risk to transform into acute myeloid leukemia (AML). Myeloid-derived suppressor cells were reported to enhance leukemia immune escape by suppressing an effective anti-tumor immune response. MPNs are a potentially immunogenic disease as shown by their response to interferon-α treatment and allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Novel immunotherapeutic approaches such as immune checkpoint inhibition, tumor vaccination, or cellular therapies using target-specific lymphocytes have so far not shown strong therapeutic efficacy. Potential reasons could be the pro-inflammatory and immunosuppressive microenvironment in the bone marrow of patients with MPN, driving tumor immune escape. In this review, we discuss the biology of MPNs with respect to the pro-inflammatory milieu in the bone marrow (BM) and potential immunotherapeutic approaches.

Citing Articles

Bone marrow immune cells and drug resistance in acute myeloid leukemia.

Zhang M, Yang Y, Liu J, Guo L, Guo Q, Liu W Exp Biol Med (Maywood). 2025; 250:10235.

PMID: 40008144 PMC: 11851207. DOI: 10.3389/ebm.2025.10235.

Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study.

Xiong H, Zhang H, Bai J, Li Y, Li L, Zhang L BMC Cancer. 2024; 24(1):531.

PMID: 38671390 PMC: 11046808. DOI: 10.1186/s12885-024-12301-x.

Merkel cell carcinoma in collision with squamous cell carcinoma and basal cell carcinoma in a patient on ruxolitinib treatment for myeloproliferative neoplasm.

Barrera-Penagos V, Castellanos-Leguizamon D, Hakim-Tawil J, Santivanez J, Rodriguez-Urrego P, Hiromi Lopez-Takegami J JAAD Case Rep. 2024; 45:98-101.

PMID: 38434601 PMC: 10907503. DOI: 10.1016/j.jdcr.2024.01.024.

Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E Cancer Res Commun. 2024; 4(2):365-377.

PMID: 38300528 PMC: 10860538. DOI: 10.1158/2767-9764.CRC-23-0389.

PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Milosevic Feenstra J, Jager R, Schischlik F, Ivanov D, Eisenwort G, Rumi E Am J Hematol. 2022; 97(4):390-400.

PMID: 35015307 PMC: 9306481. DOI: 10.1002/ajh.26461.

References

Busfield S, Biondo M, Wong M, Ramshaw H, Lee E, Ghosh S . Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014; 28(11):2213-21. DOI: 10.1038/leu.2014.128. View

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

Le Bousse-Kerdiles M, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F . Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996; 88(12):4534-46. View

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

Tasdemir S, Sener E, Akalin H, Keklik M, Kaynar L, Ozkul Y . Does the level of WT1 expression predict the outcome in Philadelphia-negative myeloproliferative neoplasms?. Genet Test Mol Biomarkers. 2015; 19(4):222-4. DOI: 10.1089/gtmb.2014.0281. View

Riley C, Brimnes M, Hansen M, Jensen M, Hasselbalch H, Kjaer L . Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2015; 97(1):83-92. DOI: 10.1111/ejh.12687. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C . Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104(3):865-72. DOI: 10.1182/blood-2003-11-3750. View

Nievergall E, Ramshaw H, Yong A, Biondo M, Busfield S, Vairo G . Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2013; 123(8):1218-28. DOI: 10.1182/blood-2012-12-475194. View

10.

Mullally A, Bruedigam C, Poveromo L, Heidel F, Purdon A, Vu T . Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013; 121(18):3692-702. PMC: 3643767. DOI: 10.1182/blood-2012-05-432989. View

11.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

12.

Lasho T, Jimma T, Finke C, Patnaik M, Hanson C, Ketterling R . SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012; 120(20):4168-71. DOI: 10.1182/blood-2012-05-429696. View

13.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

14.

Masarova L, Bose P, Verstovsek S . The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019; 14(4):310-327. DOI: 10.1007/s11899-019-00527-7. View

15.

Rajantie J, Sale G, Deeg H, Amos D, Appelbaum F, Storb R . Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood. 1986; 67(6):1693-7. View

16.

Barbui T, Thiele J, Gisslinger H, Kvasnicka H, Vannucchi A, Guglielmelli P . The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2):15. PMC: 5807384. DOI: 10.1038/s41408-018-0054-y. View

17.

Vannucchi A, Lasho T, Guglielmelli P, Biamonte F, Pardanani A, Pereira A . Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27(9):1861-9. DOI: 10.1038/leu.2013.119. View

18.

Spivak J . The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004; 41(2 Suppl 3):1-5. DOI: 10.1053/j.seminhematol.2004.02.011. View

19.

Billiau A . Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev. 2006; 17(5):381-409. DOI: 10.1016/j.cytogfr.2006.07.001. View

20.

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R . Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020; 382(19):1800-1810. DOI: 10.1056/NEJMoa1917635. View